
Please try another search
Most of the leading biotechnology stocks have been very weak over the past couple of months. The SPDR S&P Biotech ETF (NYSE:XBI) and iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) have both declined by more than 10 percent since early April 2019. Unfortunately for this industry group there looks to be more downside in the cards, near term.
One particular biotech stock that has been under pressure recently is Amgen (NASDAQ:AMGN), which traded as high as $196.87 a share on April 5, 2019. Today the stock is trading at $168.72, so traders and investors can easily see that it has declined sharply in a short time span. Shares of AMGN are now trading below their 200-week moving average, which puts the stock in a weak technical position and signals further declines to comes. Amgen looks to have a lot of support around the $160 level – an area that should be defended when initially tested. It is also a level that was supported in June 2017 and that tells me this trade area should provide a nice bounce for the stock.
Advanced Micro Devices Inc (NASDAQ:AMD)'s shares opened 4.4% higher on Thursday after the company launched a new AI chip it claims can challenge Nvidia (NASDAQ:NVDA)'s dominance. ...
After November's surge, investors are wondering if December will sustain the trend. In an era where the average equity holding period is merely 6 months, this is...
For much of the past month and a half, the S&P 500 has rallied, recovering all of the lost ground from the summer/fall correction. The market is currently trading at just below its...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.